Paul W. Hoelscher - 28 Jul 2021 Form 4 Insider Report for Horizon Therapeutics Public Ltd Co

Role: EVP, CFO
Signature: /s/ Miles W. McHugh, Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 28 Jul 2021
Net transactions value: -$395,445
Form type: 4
Filing time: 30 Jul 2021, 16:25:05 UTC
Previous filing: 14 May 2021
Next filing: 30 Dec 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	HZNP	Ordinary Shares	Award	$0	+8,708	+255%	$0.000000	12,119	28 Jul 2021	Direct	F1, F2
transaction	HZNP	Ordinary Shares	Tax liability	$395,445	-3,858	-32%	$102.50	8,261	28 Jul 2021	Direct
holding	HZNP	Ordinary Shares						172,226	28 Jul 2021	By Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	HZNP	Performance Restricted Stock Units (PSUs)	Award	$0	+17,418		$0.000000	17,418	28 Jul 2021	Ordinary Shares	17,418		Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On January 3, 2020, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On July 28, 2021, such performance criteria were met, and the PSUs vested as to the number of shares reported in Table I above. The remaining ordinary shares subject to the PSUs vest in equal annual installments on January 5, 2022 and January 5, 2023.
F2	Includes 1,049 ordinary shares of the Issuer acquired by the reporting person on June 1, 2021 pursuant to an employee stock purchase program.
F3	Each PSU represents a contingent right to receive one ordinary share of the Issuer.